Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines. Please watch the video at Investors.com ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback